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Drug Resistance in Malaria: A Peruvian Research Experience
—Ryan Haley (Edited by Mandy Chesley–Park)
To begin, I’ll start with the descent. As my Boeing 747
flew over the Peruvian rainforest, I looked out the
window and stared down at strings of lights that
appeared to be either convoys of boats or small cities
along the Amazon River. Upon landing in Lima at 2
a.m., I quickly got my bags, spotted the taxi driver
holding a sign with my name, and made my way
through the screaming crowd. We raced through the
city, the driver dodging potholes and calmly talking to
me in Spanish while I tightly clutched my seat. At 4 a.m.,
after traveling for over twenty–four hours, I finally
arrived at my apartment with two hours to sleep before
I had to get ready for work. I opened my journal, noted
The author at the US laboratory outpost in the Amazon.
the date and time, and wrote “70 days left.” My arrival
officially marked the first day of my summer 2007
research experience working for the United States Navy as a medical scientist studying malaria. Previously, I
had known the disease only through textbooks and movies, but a summer in Peru would certainly change that.

An Introduction to the Problem
Malaria is caused by several different species of bacteria, but Plasmodium falciparum is the name of the
single–celled parasite most widely known to cause this infectious disease (1). The parasite is transmitted by
mosquitoes to humans, where it infects red blood cells and multiplies within them. These cells eventually
rupture releasing more parasites that can restart the process in the human body or enter another mosquito
and in turn spread infection. The parasite lodges itself in the host’s liver, meaning that those who survive an
initial infection may later be reinfected when the parasite becomes active again (2).
Malaria strikes over 500 million people annually, causing fatigue, high fever, severe chills, sweats, nausea, and
vomiting, which can result in up to 2.7 million deaths each year, mostly in children (2). Several anti–malarial
drugs, including quinine, have been developed in efforts to prevent reinfection by inhibiting the parasite’s
ability to draw sustenance from human blood cells (1,3). However, just as the overuse of anti–bacterial drugs
has created drug resistant strains of bacteria, the overuse of anti–malarial drugs can create drug resistant
strains of malaria. In parts of the world where overuse of a single drug is prevalent, such as the jungles of

Southeast Asia, central Africa, and northern South America, strains of bacteria resistant to this drug have been
discovered (4,5). As a result, doctors are finding themselves unable to treat a disease that was once
treatable.
My reason for traveling to Peru was to investigate this drug resistance at the genetic level. I went with the
knowledge that the parasite’s resistance to several anti–malarial drugs has been shown to correlate with the
number of copies of the pfmdr1 (Plasmodium falciparum multiple drug resistance 1) gene present (6). This
gene is found within both resistant and non–resistant strains of the bacteria Plasmodim falciparum, but its
mutation is what gives the parasite drug resistance (6). When the pfmdr1 gene mutates, the protein the gene
codes for also changes. The modified protein makes the organism resistant to a large number of anti–malarial
drugs. Having more than one copy of this gene further enhances the parasite’s drug resistance by increasing
the rate of protein production. This is similar to having multiple workers help build a house: just as a house is
built faster with more manpower, drug resistance of the malaria parasite builds with greater numbers of the
mutated pfmdr1 gene. The goal of my study was to learn if the malaria strains circulating in the Peruvian
Amazon carried multiple copies of this gene, or if other factors were responsible for drug resistance in this
region.
To answer my research question I spent the majority of my
time at the main US military laboratory in Lima. Here I
separated out DNA from infected patients’ blood samples
and performed real–time polymerase chain reaction (PCR), a
process in which millions of copies of a small section of the
pfmdr1 gene are made from the parasite’s DNA using two
tiny strands of DNA called primers. This process was
repeated, allowing the primers to attach to both the newly
created DNA and the original parasite’s DNA. I then
compared the patients’ samples to the lab–grown samples
and determined how many copies of pfmdr1 were present in
the parasite infecting each patient.

The author with fellow researchers at the main
US laboratory in Lima.

Fieldwork in the Peruvian Amazon
After six weeks of lab work in Lima, my mentor, Lt. Dr. Bacon, asked me to travel with him into the Amazon to
get an overview of his malaria project. After spending the first day with Dr. Bacon and other research
scientists, I would then be left to work alongside a physician for eleven days in the rainforest. I was excited to
witness firsthand the importance of my laboratory work.
As we landed in Iquitos, a small city located on the Amazon River, an unbearable wave of heat washed over
me, and I instantly started to sweat in my slacks and long–sleeved dress shirt. The airport consisted of a small
building and a slab of pavement seemingly dropped in the middle of the rainforest. Our driver took us to the
military base, zooming through narrow streets filled with open air markets; houses painted in vibrant whites,
reds, blues, and yellows; and thousands of people wandering in loose–fitting clothes and flip–flops. I received
a tour of the laboratory facilities and then spent the rest of the day traveling to one of the three malaria field
sites from where my lab samples had come. We traveled up river on a long, slender single–engine boat to the
village of Padre Cocha. On a hill stood a small cement health clinic occupied by a Peruvian infectious disease
physician and a laboratory technician. The building’s paint was chipping and both the door and windows were
missing. There were no malaria patients that day; a slow day, but it was the dry season.

The next day Dr. Bacon and the other scientists left
Iquitos. I met with the Peruvian physician, a thin man
named Soloman, and we traveled to a different site. This
tiny village was made up of wooden homes with thatched
roofs of palm leaves. The clinic was similar to the one in
Padre Cocha, except that this day we had business.
Several little boys sat on a wooden bench outside the
clinic; one, wearing a pair of flip–flops, shorts, and a
Mickey Mouse sweat shirt, was visibly shaking and
sweating. He crossed his arms tightly, huddling to stay
warm despite the intense heat of the jungle.
The author and infectious disease physician Soloman
Durant traveling by boat to a remote Amazon village.

“That one looks like a malaria patient for the study,”
Soloman told me. After examining the boy and taking a
blood sample, we looked under the microscope and quickly recognized infected blood cells. The boy would
make a good patient for our study. This was just one of many malaria patients I saw in my short visit to
Iquitos; returning to Lima, I knew that their blood samples wouldn’t be far behind me.

The “Big Picture”
Back in Lima, I began to understand the larger picture and purpose of my work. I spent the remainder of my
days in Peru analyzing hundreds of new samples from individuals infected with malaria. I tested each sample
three times to ensure the number of pfmdr1 copies I was observing was correct. In all of these samples I did
not find a single infected patient whose sample possessed two or more pfmdr1 genes. These results showed
that increased anti–malarial drug resistance in Peru is not simply due to the presence of multiple copies of the
pfmdr1 gene; rather, there is more to it.
Although this was not the answer I had anticipated, because
of my research there is now one less possible reason for
increased anti–malarial drug resistance in Peru, making it
easier for scientists to identify the true reason. My data
showed that this type of testing could be used in other
countries whose populations are infected with malaria to
develop more appropriate methods of treatment and slow
down the spread of drug–resistant strains. While malaria
may not be a large problem here in the United States, it is
important to know that millions of people suffer from this
disease. Learning how drug resistance develops will help
scientists continue to effectively treat malaria and other
diseases world wide

The author with Dr. Bacon and his research team at
a malaria clinic in Padre Cocha.

On my last day, after saying my goodbyes and returning from work, I packed my belongings to leave the
country I had come to call home. Although I would be returning to the United States, the important work I did
in Peru would continue on in other researchers’ hands. One last race through the city, a good conversation in
Spanish with the taxi driver, and I arrived at the same airport where my summer research experience had
begun.

Later, as I went through US customs in Georgia, a tall, thin woman in a red airport suit looked over my
passport carefully. She raised her head, smiled, and in beautiful English said, “Good morning sir, you’ve been
gone a long time. Welcome home.” I was home. So much had happened to me; I had done and seen things I
never could have imagined. I learned the answer to my research question, and learned a lot about myself as
well. My summer in Peru was the most difficult thing I have ever done in almost every way, but it was by far
the most rewarding.
I would like to thank the Hamel Center for Undergraduate Research for their financial support of my study
through a Summer Undergraduate Research Fellowship (SURF) Abroad. I would also like to thank Dr. Louis Tisa
of the University of New Hampshire Department of Microbiology for his expert help in writing the grant
proposal, the final report, and overall as my sponsor. Finally, I would like to thank Lt. Dr. David Bacon for
hosting me both as a researcher and as a visiting scientist. His unique style of mentoring has, for me, been
incredibly influential in my discovery of the scientific process.
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